Pàgina inicial > Resultats de la cerca: Makris, Lukas
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
10 p, 384.2 KB Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy / Ilson, David H. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Prokharau, Aliaksandr (Minsk City Clinical Oncology Dispensary) ; Arkenau, Hendrik-Tobias (University College London) ; Ghidini, Michele (Azienda Ospedaliera di Cremona) ; Fujitani, Kazumasa (Osaka General Medical Center) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Mansoor, Wasat (The Christie NHS Foundation Trust (Regne Unit)) ; Zhavrid, Edvard (Alexandrov National Cancer Centre of Belarus) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; George, Ben (Medical College of Wisconsin) ; Catenacci, Daniel (University of Chicago) ; McGuigan, Sandra (Taiho Oncology Inc) ; Makris, Lukas (Stathmi Inc) ; Doi, Toshihiko (National Cancer Center Hospital East (Japó)) ; Shitara, Kohei (National Cancer Center Hospital East (Japó)) ; Universitat Autònoma de Barcelona
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy. [...]
2019 - 10.1001/jamaoncol.2019.3531
JAMA Oncology, Vol. 6 (october 2019)  
Registre complet - Creative Commons
2.
8 p, 1.6 MB Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer : a subgroup analysis from the phase 3 TAGS study / Mansoor, Wasat (The Christie NHS Foundation Trust) ; Arkenau, Hendrik-Tobias (University College London) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Shitara, Kohei (National Cancer Center Hospital East) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Cuffe, Sinead (St. James's Hospital ( Dublín, Irlanda)) ; Dvorkin, Mikhail (Omsk Regional Clinical Centre of Oncology) ; Park, David (St, Joseph Heritage Healthcare) ; Ando, Takayuki (University of Toyama) ; Van Den Eynde, Marc (UCL Cliniques Universitaires Saint-Luc) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Zaniboni, Alberto (Fondazione Poliambulanza-Istituto Ospedaliero) ; Doi, Toshihiko (National Cancer Center Hospital East) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Ilson, David H. (Memorial Sloan Kettering Cancer Center) ; Makris, Lukas (Stathmi, Inc, New Hope, PA USA) ; Benhadji, Karim A. (Taiho Oncology) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Universitat Autònoma de Barcelona
Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. [...]
2021 - 10.1007/s10120-021-01156-x
Gastric Cancer, Vol. 24 (march 2021) , p. 970-977  
Registre complet - Creative Commons
3.
10 p, 2.7 MB A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer / Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ; Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ; Planchard, David (Institut Gustave Roussy (Villejuif, França)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ; Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ; Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ; Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ; Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ; Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ; Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ; Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ; Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ; Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ; Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00930-5) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00930-5
Investigational New Drugs, Vol. 38 (april 2020) , p. 1588-1597  
Registre complet - Creative Commons
4.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO open, Vol. 2 (november 2017)  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem